
Dopamine Agonists for Parkinson’s: Benefits, Risks, and Who They Suit
Dopamine agonists imitate dopamine at the receptor instead of replacing it. Levodopa is converted into dopamine by the neurons you still have; a dopamine...
Read more →
Dopamine agonists imitate dopamine at the receptor instead of replacing it. Levodopa is converted into dopamine by the neurons you still have; a dopamine...
Read more →
Gambling, compulsive shopping, binge eating and hypersexuality are recognised effects of Parkinson's medication — not a change in someone's character. They are grouped as...
Read more →
MAO-B inhibitors and COMT inhibitors do not treat Parkinson's directly. They protect dopamine from being broken down — in the brain, or before it...
Read more →
Learn when levodopa, add-on drugs, DBS, exercise, and rehabilitation may fit—and which warning signs need review.
Read more →
Learn how Parkinson's symptoms are assessed and which treatments can support movement, safety, and daily function.
Read more →
See what 12-month trial data reveal about personalized stem cell therapy for Parkinson's—and the limits behind the promising numbers.
Read more →
A clear, step-by-step guide to essential tremor treatment—from first-line pills to DBS and focused ultrasound—for daily function.
Read more →
See what tavapadon's Phase 3 trial really showed about added levodopa "on" time—and why this promising pill is not yet available.
Read more →
Find FDA-approved Parkinson's treatments, clinical trials, safety alerts, and official resources from NIH, Parkinson's Foundation, and ClinicalTrials.gov.
Read more →
Understand a new dopamine agonist coming soon, a vitamin B6 alert for current patients, and emerging therapies that may slow disease progression.
Read more →
Most Parkinson's assistance programs run indefinitely, but promotional co-pay cards and insurance changes create real deadlines—here's how to plan ahead.
Read more →
Parkinson's treatment policies change frequently, affecting medication access and specialized care coverage with real legal and practical consequences.
Read more →
Start planning your Parkinson's treatment now—building your care team and understanding your options prevents crisis decisions later.
Read more →
FDA approvals and clinical trials show real progress in Parkinson's symptom management, but the data reveal modest advances, not transformative breakthroughs.
Read more →
Parkinson's treatment costs vary dramatically by medication class, while newer drugs promise benefits that clinical trials haven't always delivered.
Read more →
Where you live in America increasingly determines how fast you can see a Parkinson's specialist and which treatments you can afford.
Read more →
Most Parkinson's medications are affordable generics, but evidence clearly identifies which ones work best.
Read more →
Start with evaluation and low-cost strategies before committing to expensive medications or specialized programs.
Read more →
Safe Parkinson's treatment requires vigilance: recognizing medication side effects before they cascade into emergencies, and maintaining communication with specialists who know your unique situation.
Read more →
New FDA-approved infusion and adaptive deep brain stimulation therapies are reshaping Parkinson's treatment options, though severe cost and regional access gaps persist.
Read more →